{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:18:47Z","timestamp":1786990727281,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ijid.2020.11.130","type":"journal-article","created":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T17:23:12Z","timestamp":1605460992000},"page":"524-528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010\u20132019)"],"prefix":"10.1016","volume":"102","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2734-3754","authenticated-orcid":false,"given":"Cecilia G.","family":"Carvalhaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2020.11.130_bib0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijid.2017.01.019","article-title":"Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study","volume":"57","author":"Arshad","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2020.11.130_bib0010","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ijid.2020.11.130_bib0015","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2020.11.130_bib0020","series-title":"M07Ed11. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard: Eleventh Edition","author":"CLSI","year":"2018"},{"key":"10.1016\/j.ijid.2020.11.130_bib0025","series-title":"M100Ed30. Performance Standards for Antimcirobial Susceptibility Testing: 30th Informational Supplement","author":"CLSI","year":"2020"},{"issue":"2","key":"10.1016\/j.ijid.2020.11.130_bib0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dky439","article-title":"Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections","volume":"74","author":"Das","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.ijid.2020.11.130_bib0035","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijantimicag.2019.01.014","article-title":"Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience","volume":"53","author":"Destache","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"24","key":"10.1016\/j.ijid.2020.11.130_bib0040","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1001\/jama.293.24.3012","article-title":"Staphylococcus aureus endocarditis: a consequence of medical progress","volume":"293","author":"Fowler","year":"2005","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ijid.2020.11.130_bib0045","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1111\/jocs.14656","article-title":"Optimizing outcomes in infective endocarditis: a comprehensive literature review","volume":"35","author":"Harky","year":"2020","journal-title":"J Card Surg"},{"issue":"5","key":"10.1016\/j.ijid.2020.11.130_bib0050","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/jac\/dks006","article-title":"Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy","volume":"67","author":"Ho","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.ijid.2020.11.130_bib0055","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1093\/jac\/dkv131","article-title":"Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline","volume":"70","author":"Lahiri","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.ijid.2020.11.130_bib0060","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","article-title":"The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients","volume":"19","author":"Lin","year":"2013","journal-title":"J Infect Chemother"},{"issue":"5","key":"10.1016\/j.ijid.2020.11.130_bib0065","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archinternmed.2008.603","article-title":"Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study","volume":"169","author":"Murdoch","year":"2009","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.ijid.2020.11.130_bib0070","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijantimicag.2019.06.025","article-title":"Off-label use of ceftaroline fosamil: a systematic review","volume":"54","author":"Pani","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.ijid.2020.11.130_bib0075","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijantimicag.2013.07.005","article-title":"Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature","volume":"42","author":"Polenakovik","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1016\/j.ijid.2020.11.130_bib0080","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1128\/AAC.47.12.3926-3934.2003","article-title":"Evolutionary models of the emergence of methicillin-resistant Staphylococcus aureus","volume":"47","author":"Robinson","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ijid.2020.11.130_bib0085","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.cmi.2019.12.014","article-title":"Impact of EUCAST, CLSI and USCAST ceftaroline breakpoint changes on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from US medical centres (2015\u20132018)","volume":"26","author":"Sader","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.ijid.2020.11.130_bib0090","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00777-18","article-title":"Evaluation of the revised ceftaroline disk diffusion breakpoints when testing a challenge collection of methicillin-resistant Staphylococcus aureus isolates","volume":"56","author":"Sader","year":"2018","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.1016\/j.ijid.2020.11.130_bib0095","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/jac\/dku085","article-title":"Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study","volume":"69","author":"Tattevin","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.ijid.2020.11.130_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2019.03.023","article-title":"Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections","volume":"25","author":"Urban","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.ijid.2020.11.130_bib0105","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2146\/ajhp160006","article-title":"Ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"74","author":"White","year":"2017","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijid.2020.11.130_bib0110","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.2147\/IDR.S226649","article-title":"In vitro activity of ceftaroline and comparators against Staphylococcus aureus isolates: results from 6 years of The ATLAS Program (2012 to 2017)","volume":"12","author":"Zhang","year":"2019","journal-title":"Infect Drug Resist"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220323249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220323249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:59:19Z","timestamp":1761119959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971220323249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":22,"alternative-id":["S1201971220323249"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2020.11.130","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010\u20132019)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2020.11.130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}